Latest news with #MorganStanleyResearch
Boston Globe
20-05-2025
- Health
- Boston Globe
Group dining while on GLP-1s? It's complicated.
All of his dining companions were on GLP-1s, a class of drugs that are increasingly used for weight loss. Most people who take them report feeling hungry less often, and when they do eat, they can feel extremely full after a few bites. Foote, a lawyer, said that the majority of his friends are on these medications, creating a new dynamic when they go out to eat. They usually order appetizers and entrees to share; his friends will take a few bites, and he will finish the rest. 'I am a 6-foot-4, 210-pound guy, and I get quite hungry,' said Foote, 36, with a laugh. Get Winter Soup Club A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter. Enter Email Sign Up They still dine out often, 'even though it's a complete charade for them.' As long as they still split the bill — which they usually do — he is fine with the arrangement. 'I think if I were a more self-conscious person, I would care that I was the only person being a little Miss Piggy over here,' he said. 'But I love food. Some people eat to live. I love to eat.' Advertisement Morgan Stanley Research analysts estimate that 24 million people, or 7 percent of Americans, will be taking a GLP-1 by 2035. As weight-loss drugs soar in popularity, diners on and off them are wrestling with a number of restaurant etiquette quandaries, and in some cases changing their dining habits as a result. Advertisement Diners on GLP-1s are figuring out which types of restaurants they feel comfortable visiting; how to leave food on their plates without insulting the chef or their dining companions; and how to get the most value out of the experience. Those not on the drugs are contending with the pros and cons of going out with people who don't do much eating. 'There is a social component to this,' said David Wiss, a nutritionist in Los Angeles with a doctorate in public health. 'We are in a period of flux and change, and people are learning how to navigate this.' Nine months ago, Will Farmer, a talent agent in London, started taking the diabetes drug Mounjaro, a GLP-1 that many have used off-label to lose weight. Shortly after, he went to a 10-course tasting meal for a work event and could only eat a little of each course. 'I was eating a quarter of a Scotch egg,' he said. The restaurant emailed the event's host to ask if everything was OK. 'They were worried I found the food disgusting,' said Farmer, 34. Now he eats only at restaurants that serve family-style dishes or small plates so it isn't as obvious when he doesn't finish his food. 'If you go to a steak restaurant, it's weird if you leave most of it,' he said. 'But when we are all sharing, the food disappears and it's not this individual shame of leaving food behind.' As a self-described foodie and a wine and spirits publicist in New York City, Lauren Wire loves to go out to eat and order a lot of dishes. 'I want to try everything,' she said. Advertisement But as soon as she sits down, she warns everyone from the server to her dining companions that she is on a GLP-1. 'The chef might come out to say hi, or I might be on a date, and I will joke that I need a box because I am on Ozempic,' said Wire, 36. 'I don't want them to think I don't like the food, and also I want to normalize this.' It's all worth the leftovers: She likes that she can save money and enjoy the same amount of food over a longer stretch of time. Wire thinks those who dine with her and are not on the drugs only benefit. 'I still over-order, and then they get to eat more of my food,' she said, laughing. Non-dinner meetings have been the hardest for Joseph Suchodolski, a fashion consultant in New York City who has taken Mounjaro for more than two years to treat his diabetes. He tends to snack during the day, and will often insist on having just a coffee at a breakfast meeting. But during a recent morning meeting in Los Angeles, he learned his companion was also on a GLP-1. 'We both ordered breakfast, and we were just moving it around the plate,' said Suchodolski, 38. When they finally shared why, they started laughing and opening up. Wiss said it's important for patients who are new to GLP-1s to consider how they might handle social situations that can arise from eating less in public. 'When people stop drinking alcohol, for example, it's helpful for them to think through how they will respond when people offer them a drink or a waiter is disappointed they don't order wine,' he said. 'We are seeing that re-created with food.' Advertisement Some people say GLP-1s have improved the experience of eating at restaurants, though. After struggling with childhood obesity, Jackson Lemay, a content creator in Atlanta, used to feel anxious that he was eating too fast or too much while dining out. He would obsess over the menu before he got to the restaurant and shame himself if he ordered something unhealthy or too large. After taking a GLP-1 for a year and a half, that 'food noise' is gone. 'It has made me feel more confident in eating in public,' said Lemay, 27. He has never enjoyed restaurants as much as he does now. There are some people not on the drugs who refuse to dine out with people on them, though they were hesitant to say so on the record. They say they're embarrassed by full plates sent back to the kitchen, or insecure about eating more than the person across the table. But Nathaly del Carmen loves being around people with smaller appetites. Her mother, sister, and many of her friends are on GLP-1s, and she estimates that at least one person at her table is on them whenever she dines out. Del Carmen, a marketing manager in New York, said she finds herself mirroring the behavior of those on the drugs, which means she eats less and doesn't feel pressure to finish her meal if she isn't hungry. 'It helps me with impulse control,' she said. Emerging research shows GLP-1s may also curb one's appetite for alcohol. Del Carmen, 31, said some of her friends on the drugs cannot have more than one or two drinks without getting violently ill, which helps her drink less. 'They are the opposite of the one friend who eggs you on to drink more or have one more martini.' Advertisement
Khaleej Times
20-05-2025
- Health
- Khaleej Times
How GLP-1 weight loss drugs like Ozempic are changing restaurant culture
Michael Foote was at dinner with three friends at Soothr, a Thai restaurant in the East Village of Manhattan, when he looked up and noticed he was the only one eating. 'We had all ordered all this food, and we were all sharing everything,' he said, 'but I was chowing down, and my friends were all taking these little baby bites.' All of his dining companions were on GLP-1s, a class of drugs that are increasingly used for weight loss. Most people who take them report feeling hungry less often, and when they do eat, they can feel extremely full after a few bites. Foote, a lawyer, said that the majority of his friends are on these medications, creating a new dynamic when they go out to eat. They usually order appetizers and entrees to share; his friends will take a few bites, and he will finish the rest. 'I am a 6-foot-4, 210-pound guy, and I get quite hungry,' said Foote, 36, with a laugh. They still dine out often, 'even though it's a complete charade for them.' As long as they still split the bill — which they usually do — he is fine with the arrangement. 'I think if I were a more self-conscious person, I would care that I was the only person being a little Miss Piggy over here,' he said. 'But I love food. Some people eat to live. I love to eat.' Morgan Stanley Research analysts estimate that 24 million people, or 7 per cent of Americans, will be taking a GLP-1 by 2035. As weight-loss drugs soar in popularity, diners on and off them are wrestling with a number of restaurant etiquette quandaries, and in some cases changing their dining habits as a result. Diners on GLP-1s are figuring out which types of restaurants they feel comfortable visiting; how to leave food on their plates without insulting the chef or their dining companions; and how to get the most value out of the experience. Those not on the drugs are contending with the pros and cons of going out with people who don't do much eating. 'There is a social component to this,' said David Wiss, a nutritionist in Los Angeles with a doctorate in public health. 'We are in a period of flux and change, and people are learning how to navigate this.' Nine months ago, Will Farmer, a talent agent in London, started taking the diabetes drug Mounjaro, a GLP-1 that many have used off-label to lose weight. Shortly after, he went to a 10-course tasting meal for a work event and could only eat a little of each course. 'I was eating a quarter of a Scotch egg,' he said. The restaurant emailed the event's host to ask if everything was OK. 'They were worried I found the food disgusting,' said Farmer, 34. Now he eats only at restaurants that serve family-style dishes or small plates so it isn't as obvious when he doesn't finish his food. 'If you go to a steak restaurant, it's weird if you leave most of it,' he said. 'But when we are all sharing, the food disappears and it's not this individual shame of leaving food behind.' As a self-described foodie in New York City, Lauren Wire loves to go out to eat and order a lot of dishes. 'I want to try everything,' she said. But as soon as she sits down, she warns everyone from the server to her dining companions that she is on a GLP-1. 'The chef might come out to say hi, or I might be on a date, and I will joke that I need a box because I am on Ozempic,' said Wire, 36. 'I don't want them to think I don't like the food, and also I want to normalise this.' It's all worth the leftovers: She likes that she can save money and enjoy the same amount of food over a longer stretch of time. Wire thinks those who dine with her and are not on the drugs only benefit. 'I still over-order, and then they get to eat more of my food,' she said, laughing. Non-dinner meetings have been the hardest for Joseph Suchodolski, a fashion consultant in New York City who has taken Mounjaro for more than two years to treat his diabetes. He tends to snack during the day, and will often insist on having just a coffee at a breakfast meeting. But during a recent morning meeting in Los Angeles, he learned his companion was also on a GLP-1. 'We both ordered breakfast, and we were just moving it around the plate,' said Suchodolski, 38. When they finally shared why, they started laughing and opening up. Wiss said it's important for patients who are new to GLP-1s to consider how they might handle social situations that can arise from eating less in public. 'When people stop drinking alcohol, for example, it's helpful for them to think through how they will respond when people offer them a drink or a waiter is disappointed they don't order grape,' he said. 'We are seeing that re-created with food.' Some people say GLP-1s have improved the experience of eating at restaurants, though. After struggling with childhood obesity, Jackson Lemay, a content creator in Atlanta, used to feel anxious that he was eating too fast or too much while dining out. He would obsess over the menu before he got to the restaurant and shame himself if he ordered something unhealthy or too large. After taking a GLP-1 for a year and a half, that 'food noise' is gone. 'It has made me feel more confident in eating in public,' said Lemay, 27. He has never enjoyed restaurants as much as he does now. There are some people not on the drugs who refuse to dine out with people on them, though they were hesitant to say so on the record. They say they're embarrassed by full plates sent back to the kitchen, or insecure about eating more than the person across the table. But Nathaly del Carmen loves being around people with smaller appetites. Her mother, sister and many of her friends are on GLP-1s, and she estimates that at least one person at her table is on them whenever she dines out. Del Carmen, a marketing manager in New York, said she finds herself mirroring the behavior of those on the drugs, which means she eats less and doesn't feel pressure to finish her meal if she isn't hungry. 'It helps me with impulse control,' she said.
Globe and Mail
19-03-2025
- Business
- Globe and Mail
The Best Vanguard ETF to Invest $1,000 in Right Now
What to invest in now -- that may seem like a tough decision, given the current economic uncertainty in the U.S. including ongoing tariff-related concerns. Investors are worried about inflation, about stock market declines, and even a potential recession. Let's say you have $1,000 to invest right now. The Vanguard International Dividend Appreciation ETF (NASDAQ: VIGI) is a strong option to consider investing in with that amount -- or any other amount. (Remember that an exchange-traded fund (ETF) is a fund that trades like a stock.) Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Dividend appreciation First off, the "dividend appreciation" in the title likely refers to the fund's goal of focusing on stocks that not only pay dividends, but that pay growing (i.e., appreciating) dividends. But let's take a moment to simply appreciate dividends. Per S&P Global: Numerous academic studies have shown that dividend-paying stocks have historically outperformed non-dividend payers. However, much of the available dividend research focuses on the U.S. and other developed markets. A study published by Morgan Stanley Research showed that there is a strong relationship between dividend yield and total return in developed and emerging markets, with this link being the strongest in emerging markets. And per Dan Lefkovitz at Morningstar in February: Both the Morningstar Global Markets ex-US High Dividend Yield Index and the Morningstar Global ex-US Dividend Growth Index have outperformed the broad market for developed- and emerging-markets stocks outside the US. Whereas their US counterparts have failed to keep up, the international dividend benchmarks have been on top for the past five years. This is great news for anyone worried about the U.S. market and looking into deploying dollars abroad. Note that one reason dividend payers outperform is that they have generally grown to a meaningful size and are generating fairly reliable income before they commit to paying a dividend. Meet the Vanguard International Dividend Appreciation ETF The ETF "seeks to track the performance of the S&P Global Ex-U.S. Dividend Growers Index." Its primary focus is on large-cap stocks from both developed and emerging markets that have been hiking their dividend payouts regularly. It excludes U.S. stocks, so any portion of your portfolio that you devote to this ETF will fully expose you to foreign companies. How has the fund performed over time? Well, as of this writing, it's up 4.5% year to date, and up 5.57% over the past year. Its three-year and five-year average annual returns are 4.18% and 7.83%, respectively. The ETF's expense ratio (annual fee) is a very modest 0.1, meaning that you'll pay $10 annually per $10,000 you have invested in it. (Vanguard is known for ultra-low fees.) The Vanguard International Dividend Appreciation ETF recently held about 327 stocks, with between 16% and 20% of its assets in healthcare, industrial, and technology stocks. Nearly half of its assets were recently in European companies, with 30% in Pacific companies, close to 9% in emerging markets, and 12.6% in North America -- excluding the U.S., of course. Here are its recent top holdings: Stock Percent of ETF SAP SE 5.85% Roche Holding AG 4.56% Novartis AG 3.85% Nestle 3.16% Sony Group 3.13% Data source: as of Jan. 31, 2025. So what's this Vanguard ETF's dividend yield? Well, it's 1.85%. That's not huge, but it's not paltry, either. It's actually well above the S&P 500 's recent yield of 1.23%. Better still, it's designed to grow. The S&P 500, for example, encompasses dividend payers and non-payers, and payers that are growing their payouts regularly along with those that are increasing their dividends minimally or not at all. So give this fund some consideration -- especially if you're worried about the state of the U.S. economy and/or you think that companies based outside the U.S. have a lot to offer. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $315,521!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,476!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $495,070!* Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon. Continue » *Stock Advisor returns as of March 17, 2025 Selena Maranjian has positions in Novartis Ag and Roche Holding AG. The Motley Fool has positions in and recommends S&P Global. The Motley Fool recommends Nestlé and Roche Holding AG. The Motley Fool has a disclosure policy.
CBS News
07-03-2025
- Business
- CBS News
Some economists think U.S. inflation is likely to rise in 2025
The Trump administration's barrage of tariffs on key U.S. trading partners and ongoing crackdown on immigration are likely to result in higher prices for American consumers and businesses, according to Wall Street analysts. Economists with Morgan Stanley Research said in a report on Friday that they expect inflation in 2025 to rise 2.5%, up from their previous forecast in December of 2.3%. Another key gauge that strips out volatile food and energy costs is now projected to reach 2.7%, up from 2.5% in the bank's earlier forecast. "We now see higher inflation in 2025 with a more pronounced and sooner re-acceleration in goods prices," the analysts wrote. "If our narrative entering the year was 'slower growth, stickier inflation' then we now think 'slower growth, firmer inflation,'" they added. Analysts at Goldman Sachs also said on Friday they're now projecting higher inflation, largely due to Mr. Trump's tariffs. Core PCE inflation, or price increases excluding food and energy costs, could rise to 3% this year, rather than sinking to 2.1% by year-end if there were no tariffs in place. The cost of food, shelter and other items remains a top economic issue around the U.S., with the soaring cost of eggs becoming a national talking point. A recent CBS News poll found that 77% of Americans say their incomes aren't keeping up with the pace of inflation. Inflation during the pandemic soared to its highest level since 1981, peaking at 9.1% in June 2022. The pace of price increases has cooled since then, but costs remain roughly 10% higher than before the COVID crisis, Federal Reserve Bank of St. Louis data shows. Recently, inflation has been moving in the wrong direction. After dipping to 2.4% in September, the closely watched Consumer Price Index has nosed up, and in January rose to an annual rate of 3% — higher than the Federal Reserve's 2% target and the fourth straight monthly increase. The Commerce Department is scheduled to release CPI data for February on March 12. Many businesses are also expecting higher prices. As of early February, manufacturers and service firms expected inflation over the next year of 3.5% and 4%, respectively, according to a Federal Reserve Bank of New York survey out this week. Companies pointed to stiffer U.S. tariffs on foreign imports, which raise their operating costs, as a major reason they're bracing for higher inflation. President Trump on Friday again suspended 25% tariffs on Canada and Mexico, the second time he has paused steeper levies on the two largest U.S. trade partners. The White House also recently raised tariffs on China by an additional 10% and has vowed to deploy broader "reciprocal tariffs" against other nations on April 2. Although the delays leave open the possibility of a breakthrough in trade talks, the whipsaw in policy makes it more challenging for businesses to plan in advance. Tighter immigration restrictions can contribute to inflation by reducing the nation's supply of labor, according to economists. "One factor that we think limits services disinflation is reduced immigration, which could lead to labor shortages in many face-to-face service sectors (retail, restaurants, leisure, hospitals) that could result in supply-side driven inflation," the Morgan Stanley analysts said in their report. Persistent inflation could deter the Fed from moving to nudge down interest rates and lower borrowing costs for consumers and businesses, experts note. About 1 in 10 economists polled by FactSet expect the central bak to cut rates at its next meeting on March 19.
